Home / Services / CTD Service (Regulatory Dossier Preparation)

CTD Service (Regulatory Dossier Preparation)

Expert preparation, formatting, and submission support for CTD and eCTD registration dossiers aligned with EDA and international standards.

ICH CTDeCTD Electronic PublishingModule 3 CMCEDA Approved

Service Overview

Navigating pharmaceutical regulatory approvals requires absolute precision, technical accuracy, and adherence to evolving Common Technical Document (CTD) and electronic CTD (eCTD) specifications. A well-prepared regulatory dossier streamlines product registration, reduces approval timelines, and eliminates costly regulatory delays.

QEEMA Egypt provides end-to-end regulatory dossier preparation and consulting as part of our full suite of Regulatory Affairs Services. Our regulatory affairs experts and pharmaceutical scientists support human drugs, biologicals, and medical devices in compiling robust Modules 1 through 5 in full alignment with the Egyptian Drug Authority (EDA), WHO, EMA, and US FDA requirements.

Core Scope & Technical Deliverables

Preparation & Compilation of CTD/eCTD Dossiers

Assembling complete, audit-ready electronic and paper registration dossiers structured strictly per ICH CTD guidelines.

  • ICH CTD Modules 1-5 structuring
  • Hyperlinking & bookmarking validation
  • eCTD XML publishing readiness
Review & Formatting of Modules 1–5

Thorough technical review of administrative details (Module 1), summaries (Module 2), quality data (Module 3), non-clinical (Module 4), and clinical reports (Module 5).

  • Administrative Module 1 alignment
  • Module 2 Quality Overall Summaries (QOS)
  • Clinical & non-clinical summary verification
Module 3 (Quality & CMC Documentation)

In-depth preparation of technical documentation covering API characterization, formulation development, analytical method validation, and stability study data.

  • API & finished product specs
  • Method validation protocols
  • Real-time & accelerated stability data
Regulatory Deficiency Letter Support

Technical analysis and response drafting for deficiency letters issued by EDA or international health authorities to secure rapid product approval.

  • Deficiency comment gap audit
  • Scientific response drafting
  • Authority technical liaisons

Implementation Methodology

1
Gap Analysis & Data Audit

Assessing existing product data against target regulatory authority guidelines to identify missing technical reports.

2
Module Structuring & Drafting

Formatting data into standard ICH CTD sections, ensuring hyperlinking, bookmarking, and technical consistency across all modules.

3
Technical Review & Verification

Independent QA verification of analytical validation, stability data, and validation reports included in Module 3.

4
Submissions & Lifecycle Maintenance

Assisting with formal dossier submission, managing post-approval variations, and preparing annual renewals.

Target Sectors & Applications

Our specialized consulting services cater to:

Human finished pharmaceutical generic and brand product manufacturers.
Biopharmaceutical and biosimilar producers.
Medical device and IVD manufacturers entering EDA registration.
Pharma importers and exporters operating across the MENA region.

Frequently Asked Questions

Module 3 is the Quality section (Chemistry, Manufacturing, and Controls - CMC). It contains detailed data on active pharmaceutical ingredients (API), finished product specifications, manufacturing processes, process validation, stability testing, and packaging. Regulators inspect Module 3 most strictly during technical evaluations.

When the EDA issues deficiency comments, QEEMA analyzes the technical gaps, performs necessary protocol reviews or supplementary calculations, and drafts clear scientific responses to satisfy the evaluator's queries promptly.